Posts

I follow-up to our October 6, 2018 post describing emicizumab (HemLibra), I have correspondence dated 9/10/18 from Paul Riley, PhD, MBA, Stago Scientific Business Development Manager for North America. Paul writes, "I was wondering if you should put something on FF abouf emicizumab, like a survey to find out how people are deiling with it and if they have patients transitioning to that therapy. Here is some information I put together recenly on it in order to give good guidance to our customers when the have questions. There is another approval expected shortly for non-inhibitor patients transitioned over despite there having been several deaths reported recently in patients taking emicizumab." Added by George, this approval is now in place. Paul provides this table for hemophilia A monitoring.   Hemophilia A1 Therapy Classes and Monitoring FVIII Inhibitor? Y/N Y/N Y/N Prophylaxis Conventional half-life recombinant or plasma-derived FVIII concentrate Extended half-life recombinant FVIII concentrate Emicizumab Assay for measuring activity OSA or CSA2 OSA3 or CSA using human or bovine materials CSA with human materials or OSA using emicizumab calbrators and controls.4